- Home
- CMPR vs APGE Comparison
CMPR vs APGE Comparison
Compare CMPR & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPR
- APGE
- Stock Information
- Founded
- CMPR 1994
- APGE 2022
- Country
- CMPR Ireland
- APGE United States
- Employees
- CMPR N/A
- APGE N/A
- Industry
- CMPR Publishing
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CMPR Consumer Discretionary
- APGE Health Care
- Exchange
- CMPR Nasdaq
- APGE Nasdaq
- Market Cap
- CMPR N/A
- APGE 1.8B
- IPO Year
- CMPR N/A
- APGE 2023
- Fundamental
- Price
- CMPR $45.19
- APGE $39.72
- Analyst Decision
- CMPR Strong Buy
- APGE Strong Buy
- Analyst Count
- CMPR 2
- APGE 4
- Target Price
- CMPR $91.00
- APGE $91.33
- AVG Volume (30 Days)
- CMPR 243.7K
- APGE 789.4K
- Earning Date
- CMPR 04-30-2025
- APGE 03-03-2025
- Dividend Yield
- CMPR N/A
- APGE N/A
- EPS Growth
- CMPR 281.41
- APGE N/A
- EPS
- CMPR 6.02
- APGE N/A
- Revenue
- CMPR $3,357,327,000.00
- APGE N/A
- Revenue This Year
- CMPR $5.20
- APGE N/A
- Revenue Next Year
- CMPR $4.13
- APGE $795.25
- P/E Ratio
- CMPR $7.40
- APGE N/A
- Revenue Growth
- CMPR 4.60
- APGE N/A
- 52 Week Low
- CMPR $41.01
- APGE $29.10
- 52 Week High
- CMPR $104.92
- APGE $68.21
- Technical
- Relative Strength Index (RSI)
- CMPR 43.63
- APGE 55.27
- Support Level
- CMPR $41.01
- APGE $38.18
- Resistance Level
- CMPR $44.44
- APGE $41.07
- Average True Range (ATR)
- CMPR 2.09
- APGE 2.31
- MACD
- CMPR 0.81
- APGE 0.22
- Stochastic Oscillator
- CMPR 80.23
- APGE 63.77
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.